Haemophilus Influenzae Infections Questions & Answers

1. Collins S, Vickers A, Ladhani SN, Flynn S, Platt S, Ramsay ME, et al. Clinical and Molecular Epidemiology of Childhood Invasive Nontypeable Haemophilus influenzae Disease in England and Wales. Pediatr Infect Dis J. 2016 Mar. 35 (3):e76-84. [Medline].

2. LaCross NC, Marrs CF, Gilsdorf JR. Population structure in nontypeable Haemophilus influenzae. Infect Genet Evol. 2013 Mar. 14:125-36. [Medline].

3. Moxon ER. Bacterial variation, virulence and vaccines. Microbiology. 2009 Apr. 155 (Pt 4):997-1003. [Medline].

4. Ward JI, Kenneth MZ. Haemophilus influenzae. Feigin RD, Cherry JD, Fletcher J, eds. Textbook of Pediatric Infectious Diseases. 4th ed. Philadelphia, Pa: WB Saunders and Co; 1998. 1464-1482.

5. Gilsdorf JR. What the pediatrician should know about non-typeable Haemophilus influenzae. J Infect. 2015 Jun. 71 Suppl 1:S10-4. [Medline].

6. Sakata H, Adachi Y, Morozumi M, Ubukata K. Invasive Haemophilus influenzae infections in children in Kamikawa subprefecture, Hokkaido, Japan, 2006-2015: The effectiveness of H. influenzae type b vaccine. J Infect Chemother. 2017 Jul. 23 (7):459-462. [Medline].

7. Kaufhold I, Osbahr S, Shima K, Marwitz S, Rohmann K, Drömann D, et al. Nontypeable Haemophilus influenzae (NTHi) directly interfere with the regulation of E-cadherin in lung epithelial cells. Microbes Infect. 2017 Aug 10. [Medline].

8. National Center for Immunization and Respiratory Diseases, Division of Bacterial Diseases. Haemophilus influenzae Disease (Including Hib). Centers for Disease Control and Prevention. Available at https://www.cdc.gov/hi-disease/clinicians.html. July 25, 2016; Accessed: September 26, 2017.

9. Watt JP, Wolfson LJ, O'Brien KL, Henkle E, Deloria-Knoll M, McCall N, et al. Burden of disease caused by Haemophilus influenzae type b in children younger than 5 years: global estimates. Lancet. 2009 Sep 12. 374(9693):903-11. [Medline].

10. Centers for Disease Control and Prevention. Active Bacterial Core Surveillance (ABCs) Report Emerging Infections Program Network Haemophilus influenzae, 2015. Available at https://www.cdc.gov/abcs/reports-findings/survreports/hib15.pdf. Accessed: September 11, 2017.

11. Jacups SP. The continuing role of Haemophilus influenzae type b carriage surveillance as a mechanism for early detection of invasive disease activity. Hum Vaccin. 2011 Dec 1. 7(12):[Medline].

12. Active Bacterial Core Surveillance Report, Emerging Infections Program Network Haemophilus Influenzae, 2006. Available at http://www.cdc.gov/ncidod/dbmd/abcs/survreports.hib.pdf.

13. Mahapatra T. Vaccine coverage estimation using Global Positioning System and Google Earth: A commentary. Ann Trop Med Public Health. June 22, 2017. 10:295-6. [Full Text].

14. Jin Z, Romero-Steiner S, Carlone GM, et al. Haemophilus influenzae type a infection and its prevention. Infect Immun. 2007 Jun. 75(6):2650-4. [Medline].

15. MacNeil JR, Cohn AC, Farley M, Mair R, Baumbach J, Bennett N, et al. Current epidemiology and trends in invasive Haemophilus influenzae disease--United States, 1989-2008. Clin Infect Dis. 2011 Dec. 53(12):1230-6. [Medline].

16. Ortiz-Romero MDM, Espejo-García MP, Alfayate-Miguelez S, Ruiz-López FJ, Zapata-Hernandez D, Gonzalez-Pacanowska AJ, et al. Epidemiology of Nasopharyngeal Carriage by Haemophilus influenzae in Healthy Children: A Study in the Mediterranean Coast Region. Pediatr Infect Dis J. 2017 Oct. 36 (10):919-923. [Medline].

17. Whittaker R, Economopoulou A, Dias JG, Bancroft E, Ramliden M, Celentano LP, et al. Epidemiology of Invasive Haemophilus influenzae Disease, Europe, 2007-2014. Emerg Infect Dis. 2017 Mar. 23 (3):396-404. [Medline].

18. Giufrè M, Cardines R, Brigante G, Orecchioni F, Cerquetti M. Emergence of Invasive Haemophilus influenzae Type A Disease in Italy. Clin Infect Dis. 2017 Jun 1. 64 (11):1626-1628. [Medline].

19. Tsang RS, Proulx JF, Hayden K, Shuel M, Lefebvre B, Boisvert AA, et al. Characteristics of invasive Haemophilus influenzae serotype a (Hia) from Nunavik, Canada and comparison with Hia strains in other North American Arctic regions. Int J Infect Dis. 2017 Apr. 57:104-107. [Medline].

20. Szabo BG, Lenart KS, Tirczka T, Ostorhazi E. Clinical and microbiological characteristics of adult invasive Haemophilus influenzae infections: results of a 14-year single-center experience from Hungary. Infection. 2018 Dec. 46 (6):855-860. [Medline].

21. von Gottberg A, Cohen C, Whitelaw A, Chhagan M, Flannery B, Cohen AL, et al. Invasive disease due to Haemophilus influenzae serotype b ten years after routine vaccination, South Africa, 2003-2009. Vaccine. 2011 Nov 26. [Medline].

22. Tsang RSW, Ulanova M. The changing epidemiology of invasive Haemophilus influenzae disease: Emergence and global presence of serotype a strains that may require a new vaccine for control. Vaccine. 2017 Jul 24. 35 (33):4270-4275. [Medline].

23. Singh V, Nanjappa S, Pabbathi S, Greene JN. Invasive Haemophilus influenzae Infection in Patients With Cancer. Cancer Control. 2017 Jan. 24 (1):66-71. [Medline].

24. Murphy TF. Haemophilus influenzae. Bennett JE, Dolin R, Blaser MJ, eds. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. Elsevier Health Sciences; 1-2:

25. Butler DF, Myers AL. Changing Epidemiology of Haemophilus influenzae in Children. Infect Dis Clin North Am. 2018 Mar. 32 (1):119-128. [Medline].

26. Miyahara R, Suzuki M, Morimoto K, Chang B, Yoshida S, Yoshinaga S, et al. Nosocomial Outbreak of Upper Respiratory Tract Infection With β-Lactamase-Negative Ampicillin-Resistant Nontypeable Haemophilus influenzae. Infect Control Hosp Epidemiol. 2018 Jun. 39 (6):652-659. [Medline].

27. Haemophilus Influenzae serotype b (Hib) disease. Available at http://www.cdc.gov/ncidod/dbmb/diseaseinfo/haeminfluserob_t.htm. Accessed: Feb 15, 2008.

28. Cleland G, Leung C, Wan Sai Cheong J, Francis J, Heney C, Nourse C. Paediatric invasive Haemophilus influenzae in Queensland, Australia, 2002-2011: Young Indigenous children remain at highest risk. J Paediatr Child Health. 2017 Sep 4. [Medline].

29. Gorga SM, Gilsdorf JR, Mychaliska KP. Haemophilus influenzae Serotype f Epiglottitis: A Case Report and Review. Hosp Pediatr. 2017 Jan. 7 (1):54-56. [Medline].

30. Forstner C, Rohde G, Rupp J, Schuette H, Ott SR, Hagel S, et al. Community-acquired Haemophilus influenzae pneumonia--New insights from the CAPNETZ study. J Infect. 2016 May. 72 (5):554-63. [Medline].

31. Walker WT, Jackson CL, Allan RN, Collins SA, Kelso MJ, Rineh A, et al. Primary ciliary dyskinesia ciliated airway cells show increased susceptibility to Haemophilus influenzae biofilm formation. Eur Respir J. 2017 Sep. 50 (3):[Medline].

32. Shoemark A. Haemophilus influenzae; biofilms in primary ciliary dyskinesia: a moving story. Eur Respir J. 2017 Sep. 50 (3):[Medline].

33. Sriram KB, Cox AJ, Clancy RL, Slack MPE, Cripps AW. Nontypeable Haemophilus influenzae and chronic obstructive pulmonary disease: a review for clinicians. Crit Rev Microbiol. 2017 May 25. 1-18. [Medline].

34. Tan WS, Peh HY, Liao W, Pang CH, Chan TK, Lau SH, et al. Cigarette Smoke-Induced Lung Disease Predisposes to More Severe Infection with Nontypeable Haemophilus influenzae: Protective Effects of Andrographolide. J Nat Prod. 2016 May 27. 79 (5):1308-15. [Medline].

35. Harris TM, Rumaseb A, Beissbarth J, Barzi F, Leach AJ, Smith-Vaughan HC. Culture of non-typeable Haemophilus influenzae from the nasopharynx: Not all media are equal. J Microbiol Methods. 2017 Jun. 137:3-5. [Medline].

36. Roush SW, Murphy TV. Historical comparisons of morbidity and mortality for vaccine-preventable diseases in the United States. JAMA. 2007 Nov 14. 298(18):2155-63. [Medline].

37. Price EP, Harris TM, Spargo J, Nosworthy E, Beissbarth J, Chang AB, et al. Simultaneous identification of Haemophilus influenzae and Haemophilus haemolyticus using real-time PCR. Future Microbiol. 2017 Jun. 12:585-593. [Medline].

38. Bjarnason A, Lindh M, Westin J, Andersson LM, Baldursson O, Kristinsson KG, et al. Utility of oropharyngeal real-time PCR for S. pneumoniae and H. influenzae for diagnosis of pneumonia in adults. Eur J Clin Microbiol Infect Dis. 2017 Mar. 36 (3):529-536. [Medline].

39. Dunne EM, Mantanitobua S, Singh SP, Reyburn R, Tuivaga E, Rafai E, et al. Real-time qPCR improves meningitis pathogen detection in invasive bacterial-vaccine preventable disease surveillance in Fiji. Sci Rep. 2016 Dec 23. 6:39784. [Medline].

40. Farahani H, Ghaznavi-Rad E, Mondanizadeh M, MirabSamiee S, Khansarinejad B. Specific detection of common pathogens of acute bacterial meningitis using an internally controlled tetraplex-PCR assay. Mol Cell Probes. 2016 Aug. 30 (4):261-265. [Medline].

41. Khumalo J, Nicol M, Hardie D, Muloiwa R, Mteshana P, Bamford C. Diagnostic accuracy of two multiplex real-time polymerase chain reaction assays for the diagnosis of meningitis in children in a resource-limited setting. PLoS One. 2017. 12 (3):e0173948. [Medline].

42. Abdeldaim GM, Strålin K, Korsgaard J, Blomberg J, Welinder-Olsson C, Herrmann B. Multiplex quantitative PCR for detection of lower respiratory tract infection and meningitis caused by Streptococcus pneumoniae, Haemophilus influenzae and Neisseria meningitidis. BMC Microbiol. 2010 Dec 3. 10:310. [Medline].

43. Gadsby NJ, Russell CD, McHugh MP, Mark H, Conway Morris A, Laurenson IF, et al. Comprehensive Molecular Testing for Respiratory Pathogens in Community-Acquired Pneumonia. Clin Infect Dis. 2016 Apr 1. 62 (7):817-823. [Medline].

44. Soysal A, Toprak DG, Türkoğlu S, Bakir M. Evaluation of the line probe assay for the rapid detection of bacterial meningitis pathogens in cerebrospinal fluid samples from children. BMC Microbiol. 2017 Jan 11. 17 (1):14. [Medline].

45. Roisin S, Huang TD, de Mendonça R, Nonhoff C, Bogaerts P, Hites M, et al. Prospective evaluation of a high multiplexing real-time polymerase chain reaction array for the rapid identification and characterization of bacteria causative of nosocomial pneumonia from clinical specimens: a proof-of-concept study. Eur J Clin Microbiol Infect Dis. 2018 Jan. 37 (1):109-116. [Medline].

46. Higgins O, Clancy E, Forrest MS, Piepenburg O, Cormican M, Boo TW, et al. Duplex recombinase polymerase amplification assays incorporating competitive internal controls for bacterial meningitis detection. Anal Biochem. 2018 Apr 1. 546:10-16. [Medline].

47. Bruin JP, Kostrzewa M, van der Ende A, Badoux P, Jansen R, Boers SA, et al. Identification of Haemophilus influenzae and Haemophilus haemolyticus by matrix-assisted laser desorption ionization-time of flight mass spectrometry. Eur J Clin Microbiol Infect Dis. 2014 Feb. 33 (2):279-84. [Medline].

48. Zhu B, Xiao D, Zhang H, Zhang Y, Gao Y, Xu L, et al. MALDI-TOF MS distinctly differentiates nontypable Haemophilus influenzae from Haemophilus haemolyticus. PLoS One. 2013. 8 (2):e56139. [Medline].

49. Månsson V, Gilsdorf JR, Kahlmeter G, Kilian M, Kroll JS, Riesbeck K, et al. Capsule Typing of Haemophilus influenzae by Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Mass Spectrometry. Emerg Infect Dis. 2018 Mar. 24 (3):443-452. [Medline].

50. Takeuchi N, Segawa S, Ishiwada N, Ohkusu M, Tsuchida S, Satoh M, et al. Capsular serotyping of Haemophilus influenzae by using matrix-associated laser desorption ionization-time of flight mass spectrometry. J Infect Chemother. 2018 Jul. 24 (7):510-514. [Medline].

51. Topaz N, Boxrud D, Retchless AC, Nichols M, Chang HY, Hu F, et al. BMScan: using whole genome similarity to rapidly and accurately identify bacterial meningitis causing species. BMC Infect Dis. 2018 Aug 15. 18 (1):405. [Medline].

52. Singleton R, Hammitt L, Hennessy T, et al. The Alaska Haemophilus influenzae type b experience: lessons in controlling a vaccine-preventable disease. Pediatrics. 2006 Aug. 118(2):e421-9. [Medline].

53. Kiedrowska M, Kuch A, Żabicka D, Waśko I, Ronkiewicz P, Wasiak K, et al. Beta-lactam resistance among Haemophilus influenzae isolates in Poland. J Glob Antimicrob Resist. 2017 Aug 14. [Medline].

54. Li JP, Hua CZ, Sun LY, Wang HJ, Chen ZM, Shang SQ. Epidemiological Features and Antibiotic Resistance Patterns of Haemophilus influenzae Originating from Respiratory Tract and Vaginal Specimens in Pediatric Patients. J Pediatr Adolesc Gynecol. 2017 Jun 16. [Medline].

55. Maddi S, Kolsum U, Jackson S, Barraclough R, Maschera B, Simpson KD, et al. Ampicillin resistance in Haemophilus influenzae from COPD patients in the UK. Int J Chron Obstruct Pulmon Dis. 2017. 12:1507-1518. [Medline].

56. Tsang RSW, Shuel M, Whyte K, Hoang L, Tyrrell G, Horsman G, et al. Antibiotic susceptibility and molecular analysis of invasive Haemophilus influenzae in Canada, 2007 to 2014. J Antimicrob Chemother. 2017 May 1. 72 (5):1314-1319. [Medline].

57. Tribuddharat C, Srifuengfung S. Multiple drug resistance in Haemophilus influenzae isolated from patients in Bangkok, Thailand. J Glob Antimicrob Resist. 2017 Jun. 9:121-123. [Medline].

58. Deguchi T, Ito S, Hatazaki K, Horie K, Yasuda M, Nakane K, et al. Antimicrobial susceptibility of Haemophilus influenzae strains isolated from the urethra of men with acute urethritis and/or epididymitis. J Infect Chemother. 2017 Jun 12. [Medline].

59. Wajima T, Seyama S, Nakamura Y, Kashima C, Nakaminami H, Ushio M, et al. Prevalence of macrolide-non-susceptible isolates among β-lactamase-negative ampicillin-resistant Haemophilus influenzae in a tertiary care hospital in Japan. J Glob Antimicrob Resist. 2016 Sep. 6:22-26. [Medline].

60. Van PH, Binh PT, Minh NH, Morrissey I, Torumkuney D. Results from the Survey of Antibiotic Resistance (SOAR) 2009-11 in Vietnam. J Antimicrob Chemother. 2016 May. 71 Suppl 1:i93-102. [Medline].

61. Torumkuney D, Gur D, Soyletir G, Gurler N, Aktas Z, Sener B, et al. Results from the Survey of Antibiotic Resistance (SOAR) 2002-09 in Turkey. J Antimicrob Chemother. 2016 May. 71 Suppl 1:i85-91. [Medline].

62. Jamsheer A, Rafay AM, Daoud Z, Morrissey I, Torumkuney D. Results from the Survey of Antibiotic Resistance (SOAR) 2011-13 in the Gulf States. J Antimicrob Chemother. 2016 May. 71 Suppl 1:i45-61. [Medline]. [Full Text].

63. Hu F, Zhu D, Wang F, Morrissey I, Wang J, Torumkuney D. Results from the Survey of Antibiotic Resistance (SOAR) 2009-11 and 2013-14 in China. J Antimicrob Chemother. 2016 May. 71 Suppl 1:i33-43. [Medline].

64. Torumkuney D, Chaiwarith R, Reechaipichitkul W, Malatham K, Chareonphaibul V, Rodrigues C, et al. Results from the Survey of Antibiotic Resistance (SOAR) 2012-14 in Thailand, India, South Korea and Singapore. J Antimicrob Chemother. 2016 May. 71 Suppl 1:i3-19. [Medline].

65. Kacou-Ndouba A, Revathi G, Mwathi P, Seck A, Diop A, Kabedi-Bajani MJ, et al. Results from the Survey of Antibiotic Resistance (SOAR) 2011-14 in the Democratic Republic of Congo, Ivory Coast, Republic of Senegal and Kenya. J Antimicrob Chemother. 2016 May. 71 Suppl 1:i21-31. [Medline].

66. Zafar A, Hasan R, Nizamuddin S, Mahmood N, Mukhtar S, Ali F, et al. Antibiotic susceptibility in Streptococcus pneumoniae, Haemophilus influenzae and Streptococcus pyogenes in Pakistan: a review of results from the Survey of Antibiotic Resistance (SOAR) 2002-15. J Antimicrob Chemother. 2016 May. 71 Suppl 1:i103-9. [Medline].

67. Satola SW, Collins JT, Napier R, et al. Capsule gene analysis of invasive Haemophilus influenzae: accuracy of serotyping and prevalence of IS1016 among nontypeable isolates. J Clin Microbiol. 2007 Oct. 45(10):3230-8. [Medline].

68. Scarborough M, Gordon SB, Whitty CJ, et al. Corticosteroids for bacterial meningitis in adults in sub-Saharan Africa. N Engl J Med. 2007 Dec 13. 357(24):2441-50. [Medline].

69. van de Beek D, de Gans J, McIntyre P, et al. Corticosteroids for acute bacterial meningitis. Cochrane Database Syst Rev. 2007. (1):CD004405. [Medline].

70. Brouwer MC, McIntyre P, Prasad K, van de Beek D. Corticosteroids for acute bacterial meningitis. Cochrane Database Syst Rev. 2015 Sep 12. CD004405. [Medline].

71. Gudina EK, Tesfaye M, Adane A, Lemma K, Shibiru T, Wieser A, et al. Adjunctive dexamethasone therapy in unconfirmed bacterial meningitis in resource limited settings: is it a risk worth taking?. BMC Neurol. 2016 Aug 26. 16 (1):153. [Medline].

72. Ogunlesi TA, Odigwe CC, Oladapo OT. Adjuvant corticosteroids for reducing death in neonatal bacterial meningitis. Cochrane Database Syst Rev. 2015 Nov 11. CD010435. [Medline].

73. McIntyre PB, Berkey CS, King SM, et al. Dexamethasone as adjunctive therapy in bacterial meningitis. A meta- analysis of randomized clinical trials since 1988. JAMA. 1997 Sep 17. 278(11):925-31. [Medline].

74. [Guideline] Tunkel AR, Hartman BJ, Kaplan SL, et al. Practice guidelines for the management of bacterial meningitis. Clin Infect Dis. 2004 Nov 1. 39(9):1267-84. [Medline].

75. Peltola H, Roine I, Fernández J, Zavala I, Ayala SG, Mata AG, et al. Adjuvant glycerol and/or dexamethasone to improve the outcomes of childhood bacterial meningitis: a prospective, randomized, double-blind, placebo-controlled trial. Clin Infect Dis. 2007 Nov 15. 45 (10):1277-86. [Medline].

76. Ajdukiewicz KM, Cartwright KE, Scarborough M, Mwambene JB, Goodson P, Molyneux ME, et al. Glycerol adjuvant therapy in adults with bacterial meningitis in a high HIV seroprevalence setting in Malawi: a double-blind, randomised controlled trial. Lancet Infect Dis. 2011 Apr. 11 (4):293-300. [Medline].

77. Peltola H, Leib SL. Performance of adjunctive therapy in bacterial meningitis depends on circumstances. Pediatr Infect Dis J. 2013 Dec. 32 (12):1381-2. [Medline].

78. Syrogiannopoulos GA, Lourida AN, Theodoridou MC, et al. Dexamethasone therapy for bacterial meningitis in children: 2- versus 4-day regimen. J Infect Dis. 1994 Apr. 169(4):853-8. [Medline].

79. Lee S, Yen MT. Management of preseptal and orbital cellulitis. Saudi J Ophthalmol. 2011 Jan. 25 (1):21-9. [Medline].

80. Orbital Cellulitis. American Academy of Ophthalmology. Available at https://www.aao.org/focalpointssnippetdetail.aspx?id=1b0ef397-e539-4c0d-8608-55bb5c621c94. Accessed: September 27, 2017.

81. Lawrence R. Guidelines for the management of ADULTS with suspected epiglottitis. Nottingham University Hospitals NHS Trust. Available at https://www.nuh.nhs.uk/handlers/downloads.ashx?id=62734. December 14, 2015; Accessed: September 27, 2017.

82. Epiglottitis and Supraglottitis. Gloucestershire Hospitals NHS Foundation Trust. Available at http://www.gloshospitals.nhs.uk/en/Trust-Staff/Antibiotic-Guidelines/ENT-Guidelines/Epiglottitis/. April 23, 2014; Accessed: September 27, 2017.

83. Castellazzi L, Mantero M, Esposito S. Update on the Management of Pediatric Acute Osteomyelitis and Septic Arthritis. Int J Mol Sci. 2016 Jun 1. 17 (6):[Medline].

84. Peltola H, Pääkkönen M, Kallio P, Kallio MJ, Osteomyelitis-Septic Arthritis (OM-SA) Study Group. Prospective, randomized trial of 10 days versus 30 days of antimicrobial treatment, including a short-term course of parenteral therapy, for childhood septic arthritis. Clin Infect Dis. 2009 May 1. 48 (9):1201-10. [Medline].

85. Bradley JS. What is the appropriate treatment course for bacterial arthritis in children?. Clin Infect Dis. 2009 May 1. 48 (9):1211-2. [Medline].

86. Swamy S, Sharma, R. Duration of Treatment of Gram-Negative Bacteremia: Are Shorter Courses of Antimicrobial Therapy Feasible?. Infectious Diseases in Clinical Practice. May 2016. 24:155–160.

87. Park SH, Milstone AM, Diener-West M, Nussenblatt V, Cosgrove SE, Tamma PD. Short versus prolonged courses of antibiotic therapy for children with uncomplicated Gram-negative bacteraemia. J Antimicrob Chemother. 2014 Mar. 69 (3):779-85. [Medline].

88. Nelson AN, Justo JA, Bookstaver PB, Kohn J, Albrecht H, Al-Hasan MN. Optimal duration of antimicrobial therapy for uncomplicated Gram-negative bloodstream infections. Infection. 2017 May 6. [Medline].

89. Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, et. al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016. Crit Care Med. 2017 Mar. 45 (3):486-552. [Medline].

90. Lieberthal AS, Carroll AE, Chonmaitree T, Ganiats TG, Hoberman A, Jackson MA, et al. The diagnosis and management of acute otitis media. Pediatrics. 2013 Mar. 131 (3):e964-99. [Medline].

91. Chow AW, Benninger MS, Brook I, Brozek JL, Goldstein EJ, Hicks LA, et al. IDSA clinical practice guideline for acute bacterial rhinosinusitis in children and adults. Clin Infect Dis. 2012 Apr. 54 (8):e72-e112. [Medline].

92. Swingler G, Fransman D, Hussey G. Conjugate vaccines for preventing Haemophilus influenzae type B infections. Cochrane Database Syst Rev. 2007 Apr 18. CD001729. [Medline].

93. Salam RA, Das JK, Dojo Soeandy C, Lassi ZS, Bhutta ZA. Impact of Haemophilus influenzae type B (Hib) and viral influenza vaccinations in pregnancy for improving maternal, neonatal and infant health outcomes. Cochrane Database Syst Rev. 2015 Jun 9. CD009982. [Medline].

94. Peltola H, Roine I, Fernandez J, et al. Adjuvant glycerol and/or dexamethasone to improve the outcomes of childhood bacterial meningitis: a prospective, randomized, double-blind, placebo-controlled trial. Clin Infect Dis. 2007 Nov 15. 45(10):1277-86. [Medline].

95. Charania NA, Moghadas SM. Modelling the effects of booster dose vaccination schedules and recommendations for public health immunization programs: the case of Haemophilus influenzae serotype b. BMC Public Health. 2017 Sep 13. 17 (1):705. [Medline].

96. Bridges CB, Coyne-Beasley T, on behalf of the Advisory Committee on Immunization Practices. Advisory Committee on Immunization Practices recommended immunization schedule for adults aged 19 years or older - United States, 2014. Ann Intern Med. 2014;160(3):190-7. Available at http://annals.org/article.aspx?articleid=1819123.

97. Lowry F. ACIP issues 2014 immunization schedule for adults. Medscape Medical News. February 3, 2014. Available at http://www.medscape.com/viewarticle/820145. Accessed: February 10, 2014.

98. Robinson CL, Romero JR, Kempe A, Pellegrini C, Advisory Committee on Immunization Practices (ACIP) Child/Adolescent Immunization Work Group. Advisory Committee on Immunization Practices Recommended Immunization Schedule for Children and Adolescents Aged 18 Years or Younger - United States, 2017. MMWR Morb Mortal Wkly Rep. 2017 Feb 10. 66 (5):134-135. [Medline].

99. Prymula R, Peeters P, Chrobok V, Kriz P, Novakova E, Kaliskova E, et al. Pneumococcal capsular polysaccharides conjugated to protein D for prevention of acute otitis media caused by both Streptococcus pneumoniae and non-typable Haemophilus influenzae: a randomised double-blind efficacy study. Lancet. 2006 Mar 4. 367 (9512):740-8. [Medline].

100. Palmu AA, Jokinen J, Nieminen H, Rinta-Kokko H, Ruokokoski E, Puumalainen T, et al. Effect of pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) on outpatient antimicrobial purchases: a double-blind, cluster randomised phase 3-4 trial. Lancet Infect Dis. 2014 Mar. 14 (3):205-12. [Medline].

101. Karppinen S, Toivonen L, Schuez-Havupalo L, Teros-Jaakkola T, Waris M, Auranen K, et al. Effectiveness of the ten-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) against all respiratory tract infections in children under two years of age. Vaccine. 2019 May 16. 37 (22):2935-2941. [Medline].

102. Leroux-Roels G, Van Damme P, Haazen W, Shakib S, Caubet M, Aris E, et al. Phase I, randomized, observer-blind, placebo-controlled studies to evaluate the safety, reactogenicity and immunogenicity of an investigational non-typeable Haemophilus influenzae (NTHi) protein vaccine in adults. Vaccine. 2016 Jun 8. 34 (27):3156-63. [Medline].

103. Teo E, Lockhart K, Purchuri SN, Pushparajah J, Cripps AW, van Driel ML. Haemophilus influenzae oral vaccination for preventing acute exacerbations of chronic bronchitis and chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2017 Jun 19. 6:CD010010. [Medline].

104. Szenborn L, Osipova IV, Czajka H, Kharit SM, Jackowska T, François N, et al. Immunogenicity, safety and reactogenicity of the pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in 2-17-year-old children with asplenia or splenic dysfunction: A phase 3 study. Vaccine. 2017 Sep 25. 35 (40):5331-5338. [Medline].

105. Van Damme P, Leroux-Roels G, Vandermeulen C, De Ryck I, Tasciotti A, Dozot M, et al. Safety and immunogenicity of non-typeable Haemophilus influenzae-Moraxella catarrhalis vaccine. Vaccine. 2019 May 21. 37 (23):3113-3122. [Medline].

106. Gkentzi D, Collins S, Ramsay ME, Slack MP, Ladhani S. Revised recommendations for the prevention of secondary Haemophilus influenzae type b (Hib) disease. J Infect. 2013 Nov. 67 (5):486-9. [Medline].

107. American Academy of Pediatrics. Red Book 2006: The Report of the Committee on Infectious Disease. American Academy of Pediatrics. Haemophilus infulenzae infections. 27th ed. 2006. 310-318, 89.

108. American Academy of Pediatrics Committee on Infectious Diseases. Recommended childhood and adolescent immunization schedule: United States, 2005. Pediatrics. 2005 Jan. 115(1):182. [Medline].

109. Andrade AL, Martelli CM. Globalisation of Hib vaccination--how far are we?. Lancet. 2005 Jan 1-7. 365(9453):5-7. [Medline].

110. Barthel D, Singh B, Riesbeck K, Zipfel PF. Haemophilus influenzae Uses the Surface Protein E To Acquire Human Plasminogen and To Evade Innate Immunity. J Immunol. 2012 Jan 1. 188(1):379-85. [Medline].

111. Bozdogan B, Appelbaum PC. Macrolide resistance in Streptococci and Haemophilus influenzae. Clin Lab Med. 2004 Jun. 24(2):455-75. [Medline].

112. Centers for Disease Control and Prevention. Licensure of a Haemophilus influenzae type b (Hib) vaccine (Hiberix) and updated recommendations for use of Hib vaccine. MMWR Morb Mortal Wkly Rep. 2009 Sep 18. 58(36):1008-9. [Medline].

113. Centers for Disease Control and Prevention. Progress toward elimination of Haemophilus influenzae type b invasive disease among infants and children--United States, 1998-2000. MMWR Morb Mortal Wkly Rep. 2002 Mar 22. 51(11):234-7. [Medline].

114. Centers for Disease Control and Prevention. Updated recommendations for use of Haemophilus influenzae type b (Hib) vaccine: reinstatement of the booster dose at ages 12-15 months. MMWR Morb Mortal Wkly Rep. 2009 Jun 26. 58(24):673-4. [Medline].

115. Claesson BA, Trollfors B, Lagergard T, et al. Antibodies against Haemophilus influenzae type b capsular polysaccharide and tetanus toxoid before and after a booster dose of the carrier protein nine years after primary vaccination with a protein conjugate vaccine. Pediatr Infect Dis J. 2005 May. 24(5):463-4. [Medline].

116. Cunha BA. Cunha BA. Antibiotic Essentials. 7th ed. Royal Oak, Michigan: Physicians Press; 2008.

117. Daum R. Haemophilus influenzae. Behrman RE, Kliegman R, eds. Nelson Textbook of Pediatrics. 16th ed. Philadelphia, Pa: WB Saunders and Co; 2000. 833-837.

118. Daza P, Banda R, Misoya K, et al. The impact of routine infant immunization with Haemophilus influenzae type b conjugate vaccine in Malawi, a country with high human immunodeficiency virus prevalence. Vaccine. 2006 Sep 11. 24(37-39):6232-9. [Medline].

119. de Gans J, van de Beek D. Dexamethasone in adults with bacterial meningitis. N Engl J Med. 2002 Nov 14. 347(20):1549-56. [Medline].

120. Fickweiler K, Borte M, Fasshauer M, et al. Meningitis due to Haemophilus influenzae type f in an 8-year-old girl with congenital humoral immunodeficiency. Infection. 2004 Apr. 32(2):112-5. [Medline].

121. Gallaher TK, Wu S, Webster P, et al. Identification of biofilm proteins in non-typeable Haemophilus Influenzae. BMC Microbiol. 2006. 6:65. [Medline].

122. Garner D, Weston V. Effectiveness of vaccination for Haemophilus influenzae type b. Lancet. 2003 Feb 1. 361(9355):395-6. [Medline].

123. Gessner BD, Sutanto A, Linehan M, et al. Incidences of vaccine-preventable Haemophilus influenzae type b pneumonia and meningitis in Indonesian children: hamlet-randomised vaccine-probe trial. Lancet. 2005 Jan 1-7. 365(9453):43-52. [Medline].

124. Gold R. Epidemiology of bacterial meningitis. Infect Dis Clin North Am. 1999 Sep. 13(3):515-25, v. [Medline].

125. Hall-Stoodley L, Hu FZ, Gieseke A, et al. Direct detection of bacterial biofilms on the middle-ear mucosa of children with chronic otitis media. JAMA. 2006 Jul 12. 296(2):202-11. [Medline].

126. Kelly DF, Moxon ER, Pollard AJ. Haemophilus influenzae type b conjugate vaccines. Immunology. 2004 Oct. 113(2):163-74. [Medline].

127. Leibovitz E, Jacobs MR, Dagan R. Haemophilus influenzae: a significant pathogen in acute otitis media. Pediatr Infect Dis J. 2004 Dec. 23(12):1142-52. [Medline].

128. McVernon J, Trotter CL, Slack MP, et al. Trends in Haemophilus influenzae type b infections in adults in England and Wales: surveillance study. BMJ. 2004 Sep 18. 329(7467):655-8. [Medline].

129. Mitchell V, Walker D, Zuber P, et al. Evidenced-based decision making about Hib vaccination. Lancet. 2005 Mar 12-18. 365(9463):936-7. [Medline].

130. Moxon ER, Murphy TF. Haemophilus influenzae. Mandell GL, Bennett JE, Dolin R, eds. Mandell, Douglas and Bennett's Principles and Practice of Infectious Diseases. 5th ed. New York, NY: Churchill Livingstone; 2000. 2369-2378.

131. Murphy TF, Kasper DT. Infections due to Haemophilus influenzae, other Haemophilus species, the HACEK group, and other gram-negative bacilli. Braunwald E, Fauci AS, eds. Harrison’s Principles of Internal Medicine. 14th ed. New York, NY: McGraw-Hill; 1998. 924-928.

132. Nguyen TH, Tran TH, Thwaites G, et al. Dexamethasone in Vietnamese adolescents and adults with bacterial meningitis. N Engl J Med. 2007 Dec 13. 357(24):2431-40. [Medline].

133. Peltola H, Salo E, Saxén H. Incidence of Haemophilus influenzae type b meningitis during 18 years of vaccine use: observational study using routine hospital data. BMJ. 2005 Jan 1. 330(7481):18-9. [Medline]. [Full Text].

134. Rudan I, Campbell H. The deadly toll of S pneumoniae and H influenzae type b. Lancet. 2009 Sep 12. 374(9693):854-6. [Medline].

135. Scheifele D, Halperin S, Law B, et al. Invasive Haemophilus influenzae type b infections in vaccinated and unvaccinated children in Canada, 2001-2003. CMAJ. 2005 Jan 4. 172(1):53-6. [Medline]. [Full Text].

136. Starner TD, Zhang N, Kim G, et al. Haemophilus influenzae forms biofilms on airway epithelia: implications in cystic fibrosis. Am J Respir Crit Care Med. 2006 Jul 15. 174(2):213-20. [Medline].

137. Steinhoff M, Goldblatt D. Conjugate Hib vaccines. Lancet. 2003 Feb 1. 361(9355):360-1. [Medline].

138. Strausbaugh LJ. Haemophilus influenzae infections in adults: a pathogen in search of respect. Postgrad Med. 1997 Feb. 101(2):191-2, 195-6, 199-200. [Medline].

139. Touré FS, Kouame S, Tia H, Monemo P, Cissé A, Diané B, et al. Epidemiology of paediatric meningitis in central Côte d'Ivoire after the implementation of Haemophilus influenzae type b vaccination. New Microbiol. 2017 Jul. 40 (3):170-174. [Medline].

140. Harris TM, Rumaseb A, Beissbarth J, Barzi F, Leach AJ, Smith-Vaughan HC. Culture of non-typeable Haemophilus influenzae from the nasopharynx: Not all media are equal. J Microbiol Methods. 2017 Jun. 137:3-5. [Medline].

141. Price EP, Harris TM, Spargo J, Nosworthy E, Beissbarth J, Chang AB, et al. Simultaneous identification of Haemophilus influenzae and Haemophilus haemolyticus using real-time PCR. Future Microbiol. 2017 Jun. 12:585-593. [Medline].

142. Bjarnason A, Lindh M, Westin J, Andersson LM, Baldursson O, Kristinsson KG, et al. Utility of oropharyngeal real-time PCR for S. pneumoniae and H. influenzae for diagnosis of pneumonia in adults. Eur J Clin Microbiol Infect Dis. 2017 Mar. 36 (3):529-536. [Medline].

143. Dunne EM, Mantanitobua S, Singh SP, Reyburn R, Tuivaga E, Rafai E, et al. Real-time qPCR improves meningitis pathogen detection in invasive bacterial-vaccine preventable disease surveillance in Fiji. Sci Rep. 2016 Dec 23. 6:39784. [Medline].

Joseph Adrian L Buensalido, MD Clinical Associate Professor, Division of Infectious Diseases, Department of Medicine, Philippine General Hospital, University of the Philippines Manila College of Medicine; Specialist in Infectious Diseases, Private Practice

Joseph Adrian L Buensalido, MD is a member of the following medical societies: American Society for Microbiology, Infectious Diseases Society of America, Michigan Infectious Disease Society, Philippine College of Physicians, Philippine Medical Association, Philippine Society for Microbiology and Infectious Diseases

Disclosure: Nothing to disclose.

Anna Flor G Malundo, MD, FPCP Medical Specialist in STD/AIDS Guidance, Intervention and Prevention (SAGIP) Clinic, Section of Infectious Diseases, Department of Medicine, Philippine General Hospital, University of the Philippines Manila College of Medicine, Philippines

Anna Flor G Malundo, MD, FPCP is a member of the following medical societies: Philippine College of Physicians, Philippine Society for Microbiology and Infectious Diseases

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Charles V Sanders, MD Edgar Hull Professor and Chairman, Department of Internal Medicine, Professor of Microbiology, Immunology and Parasitology, Louisiana State University School of Medicine at New Orleans; Medical Director, Medicine Hospital Center, Charity Hospital and Medical Center of Louisiana at New Orleans; Consulting Staff, Ochsner Medical Center

Charles V Sanders, MD is a member of the following medical societies: American College of Physicians, Alliance for the Prudent Use of Antibiotics, The Foundation for AIDS Research, Southern Society for Clinical Investigation, Southwestern Association of Clinical Microbiology, Association of Professors of Medicine, Association for Professionals in Infection Control and Epidemiology, American Clinical and Climatological Association, Infectious Disease Society for Obstetrics and Gynecology, Orleans Parish Medical Society, Southeastern Clinical Club, American Association for the Advancement of Science, Alpha Omega Alpha, American Association of University Professors, American Association for Physician Leadership, American Federation for Medical Research, American Geriatrics Society, American Lung Association, American Medical Association, American Society for Microbiology, American Thoracic Society, American Venereal Disease Association, Association of American Medical Colleges, Association of American Physicians, Infectious Diseases Society of America, Louisiana State Medical Society, Royal Society of Medicine, Sigma Xi, Society of General Internal Medicine, Southern Medical Association

Disclosure: Received royalty from Baxter International for other.

Pranatharthi Haran Chandrasekar, MBBS, MD Professor, Chief of Infectious Disease, Department of Internal Medicine, Wayne State University School of Medicine

Pranatharthi Haran Chandrasekar, MBBS, MD is a member of the following medical societies: American College of Physicians, American Society for Microbiology, International Immunocompromised Host Society, Infectious Diseases Society of America

Disclosure: Nothing to disclose.

Vidya R Devarajan, MD 

Disclosure: Nothing to disclose.

Bryan A T Lim, MD Chief Fellow, Department of Medicine, Section of Infectious Diseases, Philippine General Hospital, University of the Philippines Manila College of Medicine, Philippines

Disclosure: Nothing to disclose.

Wesley W Emmons, MD, FACP Assistant Professor, Department of Medicine, Thomas Jefferson University; Consulting Staff, Infectious Diseases Section, Department of Internal Medicine, Christiana Care, Newark, DE

Wesley W Emmons, MD, FACP is a member of the following medical societies: American College of Physicians, American Medical Association, American Society of Tropical Medicine and Hygiene, Infectious Diseases Society of America, and International AIDS Society

Disclosure: Nothing to disclose.

• Print this section
• Print the entire contents of
• Print the entire contents of article